These results suggest that Aβ-related changes in soluble tau metabolism in the early disease stages may be reflected not only in CSF but also in the plasma P-tau217 pool and thus further support plasma P-tau217 as an early biomarker of AD. This evidence concerns the gene MAPT and Alzheimer disease.